DM
SPRY icon

Deerfield Management’s ARS Pharmaceuticals SPRY Stock Holding History

Deerfield Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.1M Hold
7,503,812
– – 0.63% 40
2026
Q1 		$60.3M Hold
7,503,812
– – 0.71% 42
2025
Q4 		$87.4M Hold
7,503,812
– – 1.12% 26
2025
Q3 		$75.4M Sell
7,503,812
-2,220,696
-23% -$31.9M 1.15% 27
2025
Q2 		$170M Sell
9,724,508
-790,149
-8% -$11.4M 3.08% 7
2025
Q1 		$132M Hold
10,514,657
– – 2.61% 8
2024
Q4 		$111M Sell
10,514,657
-563,270
-5% -$7.89M 2.1% 12
2024
Q3 		$161M Hold
11,077,927
– – 2.4% 7
2024
Q2 		$94.3M Hold
11,077,927
– – 1.57% 20
2024
Q1 		$113M Hold
11,077,927
– – 1.97% 16
2023
Q4 		$60.7M Hold
11,077,927
– – 1.12% 27
2023
Q3 		$41.9M Hold
11,077,927
– – 0.92% 29
2023
Q2 		$74.2M Hold
11,077,927
– – 1.58% 19
2023
Q1 		$72.1M Hold
11,077,927
– – 1.61% 19
2022
Q4 		$94.5M Buy
+11,077,927
New +$71.9M 1.96% 18

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management's SPRY Position: Q2 2026 in Review

Deerfield Management held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 7,503,812 shares worth $60.1M. The position accounts for 0.63% of the portfolio, ranked #40.

Deerfield Management first reported a position in SPRY in Q4 2022 and has held it in 15 quarters since. The position peaked at $170M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Deerfield Management held 7,503,812 shares of ARS Pharmaceuticals worth $60.1M as of Q2 2026.
  • Deerfield Management left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up 0.63% of Deerfield Management's portfolio in Q2 2026, its #40 holding.
  • Deerfield Management first reported a position in ARS Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Deerfield Management's ARS Pharmaceuticals position peaked at $170M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.